Business Description
SAB Biotherapeutics was established in 2014 and operates out of Miami Beach, Florida. The company works to create antibody-based treatments sourced from human immune proteins, targeting conditions where the body's defenses turn against itself or struggle to fight infection. Its most advanced program, SAB-142, is currently being evaluated in mid-stage trials as a repeatable, long-term treatment option for patients living with type 1 diabetes.
